Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS et al (2022) Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med 387:9–20
2. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 38:1951–1962
3. Fan P, Xu K (2023) Antibody-drug conjugates in breast cancer: marching from HER2-overexpression into HER2-low. Biochim Biophys Acta Rev Cancer 1878:188849
4. Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU et al (2022) Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol 8:1177–1183
5. Ergun Y, Ucar G, Akagunduz B (2023) Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: a systematic review and meta-analysis. Cancer Treat Rev 115:102538